Susquehanna International Group
SNDX icon

Susquehanna International Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Susquehanna International Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.1M Sell
132,800
-301,300
-69% -$6.55M ﹤0.01% 5207
2025
Q4 		$9.12M Buy
434,100
+21,100
+5% +$368K ﹤0.01% 3171
2025
Q3 		$6.36M Buy
413,000
+244,300
+145% +$3.2M ﹤0.01% 3717
2025
Q2 		$1.58M Sell
168,700
-101,600
-38% -$1.12M ﹤0.01% 6314
2025
Q1 		$3.32M Buy
270,300
+129,500
+92% +$1.83M ﹤0.01% 4450
2024
Q4 		$1.86M Sell
140,800
-101,500
-42% -$1.74M ﹤0.01% 5486
2024
Q3 		$4.66M Buy
242,300
+96,500
+66% +$1.99M ﹤0.01% 3697
2024
Q2 		$2.99M Sell
145,800
-54,900
-27% -$1.15M ﹤0.01% 4307
2024
Q1 		$4.78M Buy
200,700
+71,700
+56% +$1.6M ﹤0.01% 3700
2023
Q4 		$2.79M Sell
129,000
-448,300
-78% -$6.89M ﹤0.01% 4699
2023
Q3 		$8.38M Buy
577,300
+504,900
+697% +$9.55M ﹤0.01% 2778
2023
Q2 		$1.52M Buy
+72,400
New +$1.51M ﹤0.01% 5743
2023
Q1 		– Sell
-44,300
Closed -$1.13M – 13437
2022
Q4 		$1.13M Sell
44,300
-40,500
-48% -$945K ﹤0.01% 5902
2022
Q3 		$2.04M Buy
84,800
+500
+0.6% +$11.2K ﹤0.01% 4895
2022
Q2 		$1.62M Buy
84,300
+48,600
+136% +$810K ﹤0.01% 5353
2022
Q1 		$620K Sell
35,700
-14,600
-29% -$246K ﹤0.01% 8387
2021
Q4 		$1.1M Buy
50,300
+32,000
+175% +$591K ﹤0.01% 7045
2021
Q3 		$350K Sell
18,300
-17,200
-48% -$287K ﹤0.01% 10250
2021
Q2 		$610K Buy
35,500
+6,700
+23% +$123K ﹤0.01% 9112
2021
Q1 		$644K Sell
28,800
-29,400
-51% -$664K ﹤0.01% 8882
2020
Q4 		$1.29M Buy
58,200
+18,400
+46% +$382K ﹤0.01% 6077
2020
Q3 		$587K Sell
39,800
-325,700
-89% -$4.96M ﹤0.01% 7339
2020
Q2 		$5.42M Buy
365,500
+121,400
+50% +$1.85M ﹤0.01% 2892
2020
Q1 		$2.68M Buy
244,100
+164,900
+208% +$1.55M ﹤0.01% 3470
2019
Q4 		$695K Buy
79,200
+5,500
+7% +$40.4K ﹤0.01% 6281
2019
Q3 		$551K Sell
73,700
-8,000
-10% -$72.9K ﹤0.01% 7078
2019
Q2 		$761K Buy
81,700
+36,800
+82% +$268K ﹤0.01% 6306
2019
Q1 		$236K Buy
44,900
+28,600
+175% +$163K ﹤0.01% 7621
2018
Q4 		$73K Sell
16,300
-100,000
-86% -$548K ﹤0.01% 8349
2018
Q3 		$940K Buy
116,300
+78,000
+204% +$556K ﹤0.01% 5345
2018
Q2 		$269K Buy
38,300
+21,700
+131% +$213K ﹤0.01% 8068
2018
Q1 		$236K Buy
+16,600
New +$176K ﹤0.01% 8041

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Susquehanna International Group's SNDX Position: Q1 2026 in Review

Susquehanna International Group increased its Syndax Pharmaceuticals (SNDX) stake by 983% in Q1 2026, buying an estimated $3.88M and bringing the position to 196,621 shares worth $4.59M. The position accounts for ﹤0.01% of the portfolio, ranked #4382.

Susquehanna International Group first reported a position in SNDX in Q3 2018 and has held it in 25 quarters since. The position peaked at $17.5M in Q1 2024. 247 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Susquehanna International Group held 196,621 shares of Syndax Pharmaceuticals worth $4.59M as of Q1 2026.
  • Susquehanna International Group bought 178,468 Syndax Pharmaceuticals shares in Q1 2026, an estimated $3.88M.
  • Syndax Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4382 holding.
  • Susquehanna International Group first reported a position in Syndax Pharmaceuticals in Q3 2018 and has held it in 25 quarters since.
  • Susquehanna International Group's Syndax Pharmaceuticals position peaked at $17.5M in Q1 2024.
  • 247 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.